NCT01141257View on ClinicalTrials.gov

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Solid Tumor
Interventions
DRUG

Angiocal® (PRS-050-PEG40)

Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.

Trial Locations (2)

Unknown

Breisgau

Ruhrgebiet

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

Pieris Pharmaceuticals GmbH

INDUSTRY